TNF and Crohn disease: In a pooled cohort of patients with ankylosing spondylitis, psoriasis and psoriatic arthritis, Crohn disease, and ulcerative colitis (n = 116), exposure to TNF inhibitors was not associated with a risk of developing inflammatory CNS diseases (adjusted OR, 2.13; 95% CI, 0.90-5.05; P = .09).